When was Athira Pharma founded?

Athira Pharma was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Where is Athira Pharma located?

Athira Pharma is headquartered in Seattle, United States. It is registered at Seattle, Washington.

How many employees does Athira Pharma have?

As of May 31, 2026, the latest employee count at Athira Pharma is 51.

Is Athira Pharma a funded company?

Athira Pharma is a funded company, having raised a total of $121M across 13 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 25, 2014.

When was the latest funding round of Athira Pharma?

Athira Pharma's latest funding was a $***** Grant (prize money) round on Dec 08, 2020, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.15B in funding in 2026 to date.

Where does Athira Pharma rank among its competitors?

Athira Pharma ranks 9th amongst 537 active competitors, of which 182 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Athira Pharma?

Athira Pharma's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Tenaya Therapeutics. Among them, Alchemab secured the most recent funding round in July, 2026.

Athira Pharma - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of drugs for neurodegenerative diseases. The company's product is Fosgonimeton for the treatment of Alzheimer’s, Parkinson’s, various dementias, and others. Also, have two drug candidates ATH-1020 for neuropsychiatric indications and ATH-1019 for peripheral indications.

Website: athira.com
Social
Email ID: *****@athira.com
Phone Number: +1 **********
Registered Address: Seattle, Washington

Key Metrics

Founded Year

2011

Location

Seattle, United States

Stage

Public

Total Funding

$121M in 13 rounds

Latest Funding Round

Grant (prize money), Dec 08, 2020, $*****

Investors

Alzheimer's Drug Discovery & 23 more

Ranked

9^th among 537 active competitors

Employee Count

51 as on May 31, 2026

Similar Companies

Denali Therapeutics & 667 more

Exit Details

Public

View Athira Pharma's full profile

Athira Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ATHIRA PHARMA, INC. CIN: 453368487 , United States, Active		-	26 (As on Dec 31, 2024)	-

Athira Pharma got listed on Sep 18, 2020.

Click here to take a look at Athira Pharma's IPO in detail

Athira Pharma has raised a total funding of $121M over 13 rounds. Its first funding round was on Jul 25, 2014. Its latest funding round was a Grant (prize money) round on Dec 08, 2020 for $*****. 1 investor participated in its latest round. Athira Pharma has 22 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Athira Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 08, 2020	4996192	Grant (prize money)	8009874	8026493	1071733	2744807
Sep 15, 2020	5633602	Grant (prize money)	2894118	7024533	3767966	HHS
Jun 04, 2020	2837807	Series B	4374204	9457707	Perceptive Advisors	RTW Investments & 9 more

Access funding benchmarks and valuations. Sign up today!

View details of Athira Pharma's funding rounds and investors

Athira Pharma's employee count trend

Athira Pharma has 51 employees as of May 26. Here is Athira Pharma's employee count trend over the years:

Uncover Athira Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Athira Pharma include Denali Therapeutics, Fulcrum Therapeutics and Tenaya Therapeutics. Here is the list of Top 10 competitors of Athira Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	Fidelity Investments, RTW Investments & 7 others	70/100
4th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
5th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Blackstone, Redmile Group & 17 others	67/100
6th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	66/100
7th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
8th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
9th	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	RTW Investments, Perceptive Advisors & 22 others	65/100
10th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	64/100